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Objective: 
To analyze the oncological outcomes of men undergoing primary RPLND and characterize the use of 
adjuvant chemotherapy and template dissections. 
Methods: 
Retrospective review of Indiana University testis cancer database identified patients who underwent a 
primary RPLND between 01/2007 and 12/2017. Patients and providers were contacted to obtain 
information regarding adjuvant therapy, recurrence, and survival. Primary outcome was recurrence-free 
survival (RFS). Kaplan-Meier curves assessed survival differences stratified by pathologic stage, template 
of dissection, and use of adjuvant chemotherapy. 
Results: 
Overall, 274 patients were included. Most men presented with CS-I disease (214, 78%). A modified 
unilateral template was performed in 257 (94%) and bilateral template in 17 (6%). Overall, 148 (54%) 
and 126 (46%) of men had Pathologic Stage I (PS-I) and PS-II disease, respectively. Thirteen patients 
(10%) with PS-II disease were treated with adjuvant chemotherapy. With a median follow-up was 55 
months, only 33 (12%) patients recurred. Of the 113 patients with PS-II disease who did not receive 
chemotherapy, 21 (19%) relapsed and 81% were cured were surgery alone and never recurred. No 
difference in RFS was noted between modified and bilateral template dissections.  
Conclusions: 
The use of adjuvant chemotherapy has been minimal over the past decade. The majority (81%) of men 
with PS-II disease were cured with RPLND alone and were able to avoid chemotherapy. Modified 

















Testicular cancer is the most common solid malignancy among young males, accounting for more than 
9,000 new cases in United States annually 1, 2. Nearly 50% of patients with testis masses are diagnosed 
with non seminomatous germ cell tumors (NSGCT), one third of whom present with clinical stage I (CS-
I) disease 3.  
Management options of CS-I disease include surveillance, surgical management with a primary 
retroperitoneal lymph node dissection (P-RPLND), or chemotherapy in the form of 1 cycle of Bleomycin, 
Etoposide, and Cisplatin (BEP). P-RPLND is generally used to manage CS-I or low-volume CS-II 
NSGCT and has been shown to be curative in up to 70-90% of patients 4, 5. Previous institutional series 
noted that the rate at which patients with initial CS-I are found to have pathologic stage II (PS-II) disease 
ranges from 19-28% which confers a relapse risk of 20-36% 6. Adjuvant chemotherapy following RPLND 
in the form of 2 cycles of Bleomycin, Etoposide, and Cisplatin (BEP) has demonstrated a significant 
reduction in relapses rates in a randomized clinical trial 7. However, no difference in overall survival was 
noted between those treated with adjuvant chemotherapy following RPLND vs. those only treated at the 
time of relapse.  Thus, adjuvant chemotherapy comes at a cost of a significant burden of overtreatment if 
chemotherapy is given to all patients with PS-II disease.  Adjuvant chemotherapy usage for PS-II patients 
has been as high as 55% in previous open series and 41-100% laparoscopic/robotic series with virtually 
no recurrence recorded in those men completing therapy 8-16.   
Historically, patients opting for surgical management were treated with bilateral template and suprahilar 
dissections which were associated with some morbidity. With improved cross-sectional imaging, serum 
tumor markers, and anatomic mapping studies, dissect on templates initially began to eliminate supra-
hilar dissection 17. Later modification of the templates allowed for unilateral dissections to limit morbidity 

















In this study, we sought to examine the oncological outcomes of men undergoing primary RPLND over 




The prospectively maintained Indiana University testis cancer database was queried to identify men who 
underwent open primary RPLND for NSGCT between 01/207 and 12/2017. Patients and referring 
providers were contacted to obtain information regading receipt of adjuvant therapy, recurrence, and 
survival. Patients who could not be contacted or had incomplete information were excluded.  The clinical 
and pathologic stage of those excluded were similar to patients included in the study. 
Primary and Secondary Outcomes: 
The primary outcome was recurrence-free survival (RFS).  Recurrence was defined as development of 
metastatic disease on axial cross-sectional imaging of the chest, abdomen and pelvis and/or a rise in 
serum tumor markers with subsequent initiation of combination cisplatin-based chemotherapy.  
Recurrence-free survival was calculated from the dat of the RPLND until the date of recurrence.  
Patients were censored at the date of last follow up if they did not recur.  Secondary outcomes included a 
description of recurrence patterns, indications for adjuvant chemotherapy and overall survival (OS).  RFS 
stratified by template of dissection, pathologic stage, and receipt of adjuvant chemotherapy was also 
assessed. 
Statistical Analysis: 
Descriptive statistics including means and standard eviations (or median and interquartile ranges) were 
used for continuous variables, while counts and frequencies summarized categorical variables for the 

















and categorical variables, respectively.  Recurrence-free and overall survival was calculated and survival 
curves were constructed using the Kaplan-Meier method.  Stratified recurrence-free survival analysis 
based on template of dissection and pathological stage/adjuvant chemotherapy receipt was conducted.  
Differences in survival curves were compared with the log-rank test. All statistical analysis was 
conducted using SAS 9.4 (SAS Institute, Cary, NC) using an alpha value of 0.05. 
 
Results:  
Patient Population and Demographics: 
A total of 305 patients underwent a primary retropeitoneal lymph node dissection for NSGCT between 
2007 and 2017. Recurrence, follow up, and survival data was obtained for 274 (90%) patients. The 
median age at presentation was 28 and the vast majority were white (96%). Most men had CS-I disease 
(214, 78%) whereas 60 (22%) men were CS-II. All men had normal tumor markers preoperatively (AFP 
and hCG). Laterality of the primary tumor was right in 135 (49%) and left in 139 (51%).  Patients with 
embryonal predominance accounted for 46% and those with lymphovascular invasion (LVI) accounted 
for 37% of patients. The template of dissection wasmodified unilateral in 257 (94%) and bilateral in 17 
(6%). Reasons for bilateral template dissection included: size of RP mass intraoperatively >2 cm and 
multifocality of disease (7, 41%), bilateral RP disea e (4, 23%), bilateral synchronous primary testicular 
tumors (3, 18%), variant histology with non GCT components (2, 12%), and unknown (1, 6%). Patient 
demographics are summarized in Table 1. 
Pathological assessment: 
Overall, 148 (54%) and 126 (46%) men had pathologic stage I and stage II disease, respectively. Patients 
with CS-I and CS-II disease were noted to have PS-II disease in 35% and 87% of cases, respectively. Of 

















cell tumor (93, 74%), teratoma only (17, 13%), and pure seminoma (16, 13%). Among patients with PS-II 
disease, the median number of positive lymph nodes was 2. Notably, 13% of CS-II were ultimately found 
to be PS-I. 
Receipt of Adjuvant Chemotherapy: 
The majority of patients with pathologic stage II disease were observed with only thirteen patients (10%) 
treated with adjuvant chemotherapy. The indications f r adjuvant chemotherapy were ≥ 5 nodes positive 
(7, 54%), positive node > 5 cm (2, 15%), and patient preference (4, 31%). None of the 13 patients with
pathological stage II disease who received adjuvant chemotherapy recurred.  One-hundred and thirteen 
patients with pathological stage II disease did not receive chemotherapy.  The recurrence rate in this 
cohort was 19% (21 patients) with a median time to recurrence of 3.6 months.  Chemotherapy was 
avoided in 92 men with PS-II disease (81%) who were cur d with surgery alone.    
Recurrences: 
With a median follow-up of 55 months, 33 (12 %) patients recurred. Twenty-one patients were pathologic 
stage II and 12 patients were pathologic stage I. The median time to recurrence for the total cohort was
3.6 months with 85% of recurrences noted within 1 year of RPLND.  The rates of recurrence stratified by 
pathologic stage and receipt of adjuvant chemotherapy were: PS-I (8%, 12), PS-II without adjuvant 
chemotherapy (19%, 21), and PS-II with adjuvant chemotherapy (0%, 0). RFS curves stratified by 
pathologic stage/adjuvant chemotherapy receipt are shown in Figure 1.  The 2-year recurrence free 
survival for PS-I, PS-II without chemotherapy, and PS-II with adjuvant chemotherapy was 92%, 83%, 
and 100%, respectively. All recurrences were treated successfully with standard first-line chemotherapy. 
Of the 33 recurrences, the location of recurrence was biochemical in 7, pulmonary in 9, retroperitoneal 
only in 6, suprahilar only in 2, mediastinal in 3, and pelvic in 2. Additionally, 1 patient had simultaneous 
recurrences in both the retroperitoneum and lung, aother patient had simultaneous recurrences in the 

















carcinomatosis or liver metastases.  An anatomical description of recurrence location is illustrated in 
Figure 2. There was no significant difference in recurrence-free survival among patients who had bilateral 
template (1/17, 6%) or modified unilateral (32/257, 12%) approach. 
Seven patients (2.6%) recurred within the retroperitoneum, one of which also had simultaneous lung 
recurrence. All seven patients had PS-II disease at the time of RPLND. The location of recurrence in 
these patients consisted of in-field in 3, out-of-field in 4 (contralateral retroperitoneum). Of the 7 
retroperitoneal recurrences, 1 had a bilateral template and 6 had a modified unilateral template. Of the 257 
patients who had a unilateral modified dissection, only 4 patients (1.6%) recurred in the contralateral 
retroperitoneum.  The overall in-field recurrence rate was 1.1% (3 of 274).  
Overall Survival: 
A total of 6 patients died during follow-up and only two died from testis cancer. Disease-specific survival 
(DSS) for the entire cohort was 99.3%. Overall survival (OS) of the total cohort was 97.8%.  
When examining the 2 mortalities from testis cancer, one patient had embryonal predominant NSGCT on 
orchiectomy and was found to be PS-I on RPLND. He lat r recurred after a delay in presentation with a 
large tumor burden in the mediastinum, eventually presenting with brain metastasis despite salvage 
chemotherapy and died. The other patient had embryonal predominant NSGCT on orchiectomy and was 
PS-I on RPLND. He relapsed 2 years later with brain metastasis consistent with embryonal carcinoma as 
well as in the chest and small bowel mesentery withpat ology consistent with chondrosarcoma and 
rhabdomyosarcoma transformation. Regarding the remaining 4 mortalities, one patient expired due to a 
seizure disorder, another due to a motor vehicle accident, another due to complications from alcoholism, 




















Two changes were implemented at our institution over th  past decade. The use of modified unilateral 
template dissections was preferred in contrast to a bilateral template in appropriately selected patients. A 
left modified template consisted of performing a split and roll technique on the aorta and harvesting the 
pre-aortic, para-aortic, retroaortic, and left common iliac nodes, while a right modified template involved 
performing a split and roll technique on the aorta harvesting the pre-aortic, interaortocaval, retro-aortic, 
paracaval, retrocaval, and right common iliac nodes.  Additionally, adjuvant chemotherapy was rarely 
recommended in patients found to have PS-II disease at the time of RPLND. Despite these changes, we 
have seen no significant increase in recurrence rates with 33 recurrences recorded over a 10 period (12%). 
Although adjuvant chemotherapy was given to 10% of patients with PS-II disease, only 19% recurred and 
all were cured with first-line chemotherapy.  
The historical dogma of two cycles of adjuvant chemotherapy for all men with PS-II disease was 
evaluated in a randomized controlled trial published in 1987. 7 One rationale for this study was to avoid 3-
4 cycles of induction cisplatin-based chemotherapy in men with stage II disease due to the acute toxicity 
of chemotherapy during that time period.  Williams et al. randomized men with PS-II disease after 
primary RPLND to observation or chemotherapy.  Recurrence rates were lower in men who received 
chemotherapy and roughly half of the men who were initially observed recurred and required 
chemotherapy.  The relatively high recurrence rate of 50% in this trial is reflective of including men who 
had elevated markers at time of surgery, first generation imaging, and a number of men with bulkier 
disease compared to current studies. Despite the higher recurrence risk in the observation group, the cur
rates were similar between the groups.  It is our institutional preference to withhold adjuvant 
chemotherapy in most men to avoid overtreatment of men cured with surgery alone.  The rate of adjuvant 
chemotherapy use for men with PS-II disease in our current study (10%) is much lower than the rates 
reported in other open (50-55%) 11, 13, laparoscopic (24-100% ) 12, 14, 16, 19 and robotic (29-62%) 15, 20 series 

















our series never recurred. Our lower use of adjuvant chemotherapy limited chemotherapy exposure, and 
potential long-term toxicity associated with it, to only those men who recur, while having negligible 
effects on overall survival. Future studies analyzing oncological outcomes of either open or minimally 
invasive RPLND in the primary setting need to asses the use and perhaps overuse of adjuvant 
chemotherapy for true comparability of the operative echnique. Furthermore, it is important to note that
13% of patients with clinical stage II disease were found to have pathologic stage I disease.  This 
proportion of false “positive” with CS-II disease has previously been demonstrated by Donohue et. al 
[13].  This would serve as a cautionary note to be wary for patients with CS-II disease and normal 
markers receiving chemotherapy.  We would advise against subjecting such patients to BEPx3 or EPx4 
and potential short term and late complications given that they might already be cured with orchiectomy 
+/- RPLND alone. 
The debate regarding the template for dissection for men undergoing primary or post-chemotherapy 
RPLND is longstanding.  Modified template dissections were proposed due to the predictable nature of 
lymphatic metastasis defined with the assistance of mapping studies in an effort to limit patient morbidity 
21, 22.  Proponents of bilateral dissections in all patients argue that modified templates increase the risk of 
incomplete dissection and subsequent recurrence with need for induction chemotherapy.  In a 
retrospective analysis of 500 patients undergoing blateral template dissections, Eggener et al reportd 
rates of extra-template retroperitoneal disease in 3-23% of patients depending upon the anatomical 
boundaries of the modified template 23. Thus, the authors argue for bilateral template in all patients due to 
high rates of contralateral disease. The vast majority f patients in our series (94%) underwent a unilateral 
modified template. Yet with a median follow up of 55 months, the recurrence rate in the contralateral 
retroperitoneum after unilateral modified template was only 1.6%. Additionally, there were no differenc s 
in RFS noted between patients who had a modified unilateral vs. bilateral template.  Thus, a meticulous 
modified template dissection can be safely used to minimize morbidity while maintaining excellent 

















Our results should be viewed within the context of several limitations. This is a retrospective analysis 
which can be prone to bias and confounding factors. However, the large study size examining primary 
RPLND outcomes largely without adjuvant chemotherapy in a contemporary cohort is informative. We 
were unable to contact every patient identified who underwent a primary RPLND, nonetheless, the vast 
majority (90%) of patients had complete records rega ding follow up, recurrence and survival. 
Furthermore, patients who were unable to be contacted did not have disproportionate adverse pathology 
(88% were CS-I and 77% were PS-I). The patient’s post-operative oncologic care was not centralized and 
thus, the rationale and thresholds for offering adjuvant chemotherapy was heterogeneous as demonstrated 
with the inability to determine why 4 patients received adjuvant chemotherapy. Our oncology team 
generally works closely with referring oncologists and provides guidance regarding follow up, 
surveillance and chemotherapy use. Finally, the locati n and presence of some recurrences were not 
radiographically reviewed centrally at our institution. This could have introduced some variability in the 
exact location of the recurrence as we had to rely on radiographic reports from outside institutions for 
some patients. This was especially prevalent in patients treated prior to 2011 as most institutions 
discarded radiographic images after being archived for seven years.  
These limitations notwithstanding, we find that ourdata supports the use of surveillance and avoidance of 
adjuvant chemotherapy for most patients with pathologic stage II disease. The overall cure rate with 
surgery alone was 81%.  Furthermore, despite the high rate of unilateral modified template use, 
recurrence rates in the contralateral retroperitoneum were minimal (1.6%) and there was no difference i  
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